Grace Breeding: if Maoz succeeds, how much of the value really reaches the listed company
Maoz may create value, but that value does not automatically belong in full to Grace Breeding. The activity and the IP sit in Grace Technologies, where the listed company owns 85%, while Indofil still retains board, approval, and share-transfer rights even though it has not funded its share since 2021.
Not All of Maoz Belongs to the Stock
The main article already established that Maoz moved forward agronomically, but that the company still has not proved commercialization. This follow-up isolates a different question: even if Maoz succeeds, how much of that value actually reaches Grace Breeding shareholders.
As of April 3, 2026, the stock closed at NIS 17.59, and with 4.18 million shares outstanding the listed company was worth about NIS 73.5 million. But the market is not buying 100% of the operating platform. The nitrogen-fixation activity and patent were transferred in July 2018 into Grace Technologies, and the listed company owns only 85% of that subsidiary, while Indofil owns 15%.
That is the core of this follow-up. If Maoz creates value, that value will first be created inside Grace Technologies. Only then does the next question matter: how much of it can really move up, economically, corporately, and in cash terms, to the listed company. As of the end of 2025, the answer is clearly less than the headline story.
The chart is simple, but it organizes the whole issue. Grace Breeding shareholders do not directly own Maoz. They own a listed company that in turn owns 85% of the subsidiary where the activity sits. That is not a legal footnote. It is the value layer.
The 15% That Is Much More Than a Number
This ownership structure was not built as a loose distribution arrangement. In October 2018 Grace Technologies allotted 15% of its issued and paid-up share capital to Indofil for $1.5 million, reflecting an $8.5 million pre-money valuation. That means Indofil entered as an equity partner in the operating vehicle, not just as a distributor receiving a fee.
The more important point is that this 15% comes with rights. As long as Indofil holds more than 14% of Grace Technologies, it is entitled to appoint two directors. If its holding falls to between 8% and 14%, it is entitled to appoint one director. At the same time, as long as the listed company holds more than 60% of Grace Technologies, it is entitled to appoint three directors.
But the story does not stop at board composition. Until a first public offering of Grace Technologies, or until Indofil falls to 10% or less on a fully diluted basis, a range of decisions cannot be brought forward without Indofil’s prior approval. The filing specifically mentions related-party transactions, certain financing rounds, a material change in business activity, amendments to the articles that affect Indofil, capital changes that affect Indofil alone, and certain kinds of IPO actions. In addition, share transfers are subject to a right of first refusal, and both sides have tag-along rights.
| Layer | What the agreements say | Why it matters to listed shareholders |
|---|---|---|
| Economic ownership | Grace Breeding owns 85% and Indofil owns 15% of Grace Technologies | Even in a success scenario, the listed company’s first-layer economic exposure is not 100% |
| Board representation | Indofil is entitled to two directors above 14% and one director between 8% and 14% | The partner is not a passive financial holder sitting outside the decision room |
| Consent rights | Until an IPO or a drop to 10% or less on a fully diluted basis, some decisions require Indofil’s prior approval | Not every financing or structural move at the subsidiary is solely in the listed company’s hands |
| Share-transfer mechanics | Right of first refusal and tag-along rights apply | Even value realization through a sale is not completely frictionless |
| Funding since 2021 | The listed company has funded the activity, while Indofil has not transferred its share | The economic gap with the partner exists, but it has not yet been fully resolved in the structure |
The non-obvious point sits right here. A partner can stop funding and still retain corporate power. The company explicitly states that since 2021 Grace Breeding has funded the activity while Indofil has not transferred its share, and that discussions are ongoing for Indofil either to complete its share or to be diluted accordingly. Until that is actually resolved, the corporate layer is still very much alive.
Accounting Has Already Absorbed the Pain, the Agreements Have Not Moved Yet
The filing shows that in 2025 the non-controlling interest share of total loss was NIS 315 thousand, and the non-controlling interest balance reached a deficit of NIS 1.64 million at year-end. From an accounting perspective, the minority is already absorbing part of the loss stream into a deficit balance.
But that is precisely the point. An accounting deficit is not the same thing as a corporate exit. The governing agreements still describe board rights, consent rights, and transfer protections, and the company itself does not say those rights have been cancelled. It says only that discussions continue regarding funding completion or dilution. So a reader who looks only at the consolidated statements can miss the gap between what IFRS already allocates to the minority and what still remains open at the control and value-access level.
That is why the next phase is not only a commercialization question. It is also a corporate-order question. Without an agreed resolution or an actual dilution event, value can start building inside the subsidiary while Indofil’s influence remains meaningful even after several years of not participating in funding.
What Actually Moved Up in 2025
The filing does disclose one channel through which value can move from the subsidiary to the listed parent before any dividend exists. In June 2018 the company and Grace Technologies signed a services agreement under which the listed company provides operating, management, professional nitrogen-fixation, and administrative services to the subsidiary. The agreement includes a fixed monthly payment, expense reimbursement, and a potential additional 10% success fee.
That matters, because it means the listed parent is not dependent only on dividends to see some value moving up. But the full picture matters. In the same disclosure the filing also clarifies that the IP developed in the nitrogen-fixation field is owned by Grace Technologies. In other words, the services agreement creates a fee channel, not a re-transfer of the core asset.
That chart sharpens the gap between theoretical value and accessible value. In 2025 Grace Technologies posted a NIS 2.096 million net loss. The dividend to the listed parent was zero. Management fees the parent received or was entitled to receive were NIS 684 thousand.
That means the only live, disclosed upstream channel at this point is management fees. There is still no actual dividend path from the subsidiary to the listed company. Put differently, even if investors believe Maoz can move toward commercialization, the filing shows that in 2025 the listed-layer capture mechanism was still much thinner than the technology story itself.
What Has to Happen for the Value to Become Reachable
For future Maoz value to become genuinely reachable to Grace Breeding shareholders, it is not enough for the product to work in the field. At least three gates still have to be crossed.
The first is the ownership gate. As long as Indofil remains around 15%, listed shareholders own only 85% of the layer where the asset sits, and they do so alongside a partner that still carries board and consent rights. If Indofil completes its funding share, that structure remains. If it does not and is actually diluted, only then does part of the overhang begin to close.
The second is the practical-control gate. Until Indofil falls to 10% or less on a fully diluted basis, some material decisions remain subject to its prior approval. So even a positive move such as financing, restructuring, or preparation for a capital event at the subsidiary is not entirely one-directional from the listed parent’s perspective.
The third is the cash gate. Even if commercialization arrives first, investors still have to see how value begins to move upward. Will that happen through a more meaningful fee stream, through distributable cash, or through a subsidiary capital-markets path such as a first public offering? Without a real transmission channel, operating success at the subsidiary can remain only partly reachable at the public-shareholder layer.
There is also a fourth layer above the subsidiary itself. The listed company continues to fund the path through equity issuances of shares and options. So even if value improves at Grace Technologies, shareholders still need to ask how much of it will remain after the 15% minority at the subsidiary and after possible dilution at the listed-company level.
Bottom Line
If Maoz succeeds, the value will not reach the listed company one for one. It will first pass through Grace Technologies, where Grace Breeding owns only 85%, and through an agreement structure that still leaves Indofil with board power, certain approval rights, and transfer protections.
That does not mean Grace Breeding shareholders have no upside. It does mean the correct lens is accessible value, not only technological value. As of the end of 2025, the value that actually moved up from the subsidiary was NIS 684 thousand of management fees, with no dividend and a NIS 2.096 million net loss still sitting in the subsidiary. So the right question for 2026 is not only whether Maoz reaches first commercial use. It is also whether the value layer between Maoz and the listed company starts to open, or remains the next bottleneck.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.